26 March 2018 - - New York, New York-based nonprofit public-private partnership The Human Vaccines Project has appointed Moncef Slaoui, PhD to its board of directors, the company said.
Moncef Slaoui, PhD has led the development of numerous vaccines that are in use worldwide. He is currently a partner at Medicxi, a European venture capital firm.
Previously, Slaoui served as chairman of pharmaceutical R and D and the vaccines division at GSK.
While there, Slaoui engineered a vaccine pipeline, including vaccines against pneumococcal disease and rotavirus, as well as vaccines against shingles and Human Pappiloma Virus.
Slaoui earned a PhD in molecular biology and immunology from the Université Libre de Bruxelles in Belgium, completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine in Boston, and was a professor of Immunology at the University of Mons, Belgium.
The Human Vaccines Project's mission is to decode the human immune system to accelerate the development of vaccines and immunotherapies against major global diseases.
It brings together academic research centers, industrial partners, nonprofits and governments to address the primary scientific barriers to developing new vaccines and immunotherapies.